Currently, in the phase III trial for renal cell carcinoma and phase II trial for breast cancer, dovitinib has shown promising potential for solid tumours with an IC50 of 36 nmol/L against CSF1R [57]. This evidence concerns the gene CSF1R and breast carcinoma.